JP2021500882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500882A5 JP2021500882A5 JP2020521861A JP2020521861A JP2021500882A5 JP 2021500882 A5 JP2021500882 A5 JP 2021500882A5 JP 2020521861 A JP2020521861 A JP 2020521861A JP 2020521861 A JP2020521861 A JP 2020521861A JP 2021500882 A5 JP2021500882 A5 JP 2021500882A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric polypeptide
- region
- stalk
- polypeptide according
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023118889A JP2023153866A (ja) | 2017-10-18 | 2023-07-21 | スペーサーを含むポリペプチド組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574061P | 2017-10-18 | 2017-10-18 | |
| US62/574,061 | 2017-10-18 | ||
| PCT/US2018/056334 WO2019079486A1 (en) | 2017-10-18 | 2018-10-17 | POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118889A Division JP2023153866A (ja) | 2017-10-18 | 2023-07-21 | スペーサーを含むポリペプチド組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021500882A JP2021500882A (ja) | 2021-01-14 |
| JP2021500882A5 true JP2021500882A5 (enExample) | 2021-11-25 |
Family
ID=66096807
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521861A Pending JP2021500882A (ja) | 2017-10-18 | 2018-10-17 | スペーサーを含むポリペプチド組成物 |
| JP2023118889A Pending JP2023153866A (ja) | 2017-10-18 | 2023-07-21 | スペーサーを含むポリペプチド組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118889A Pending JP2023153866A (ja) | 2017-10-18 | 2023-07-21 | スペーサーを含むポリペプチド組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11771718B2 (enExample) |
| EP (1) | EP3697438A4 (enExample) |
| JP (2) | JP2021500882A (enExample) |
| KR (2) | KR102742741B1 (enExample) |
| CN (1) | CN111511391B (enExample) |
| AU (2) | AU2018352984B2 (enExample) |
| CA (1) | CA3079264A1 (enExample) |
| IL (2) | IL273961B2 (enExample) |
| SG (1) | SG11202003543WA (enExample) |
| WO (1) | WO2019079486A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102742741B1 (ko) * | 2017-10-18 | 2024-12-16 | 프레시전 인코포레이티드 | 스페이서를 포함하는 폴리펩타이드 조성물 |
| CA3105816A1 (en) | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
| EP3844191A4 (en) * | 2018-08-31 | 2022-06-15 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | METHODS AND COMPOSITIONS USING CHIMERIC B7H3 ANTIGEN RECEPTORS |
| AU2019377461A1 (en) * | 2018-11-06 | 2021-05-27 | Washington University | Chimeric antigen receptor memory-like (CARML) NK cells and methods of making and using same |
| US11732041B2 (en) * | 2019-04-19 | 2023-08-22 | Allogene Therapeutics, Inc. | Antibodies against 4G7-derived chimeric antigen receptors |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
| AU2020295715A1 (en) * | 2019-06-19 | 2022-02-17 | Julius-Maximilians-Universität Würzburg | Ultramodular IgG3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design |
| WO2021061862A1 (en) * | 2019-09-24 | 2021-04-01 | The Regents Of The University Of California | Notch receptors with hinge domain |
| WO2021207526A1 (en) | 2020-04-09 | 2021-10-14 | The Regents Of The University Of California | Humanized notch receptors with hinge domain |
| CN112111014A (zh) * | 2020-09-22 | 2020-12-22 | 廖文强 | 一种抗氧化嵌合型抗原受体和免疫细胞 |
| AU2022205683A1 (en) * | 2021-01-11 | 2023-07-06 | Precigen, Inc. | Chimeric receptor therapy |
| WO2022170093A2 (en) * | 2021-02-05 | 2022-08-11 | University Of Utah Research Foundation | Compositions and methods for treating with car cells |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| WO2025038646A1 (en) * | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8993524B2 (en) * | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| EP3115373B1 (en) * | 2010-09-08 | 2019-08-28 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| JP6267644B2 (ja) * | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| US20140370012A1 (en) * | 2012-01-27 | 2014-12-18 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| NZ759969A (en) | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| WO2015090229A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| DK3105335T3 (da) * | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| EP3243831A1 (en) * | 2014-02-27 | 2017-11-15 | Ucl Business Plc | Variants of the proliferation-inducing ligand (april) |
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| EP3712171A1 (en) * | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
| PT3575315T (pt) | 2014-09-15 | 2022-12-16 | Agc Biologics S P A | Recetores de antigénios quiméricos |
| AU2015330017A1 (en) * | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| WO2016168766A1 (en) | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized chimeric receptor t cell switches and uses thereof |
| ES2958720T3 (es) * | 2015-06-10 | 2024-02-13 | Immunitybio Inc | Células NK-92 modificadas para tratar el cáncer |
| CN107709356A (zh) | 2015-06-26 | 2018-02-16 | 南加利福尼亚大学 | 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞 |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| JP6976960B2 (ja) * | 2015-11-27 | 2021-12-08 | カーサリクス プロプライエタリー リミテッド | 遺伝子改変された細胞およびその使用 |
| WO2017214207A2 (en) | 2016-06-06 | 2017-12-14 | Juno Therapeutics, Inc. | Methods for the treatment of b cell malignancies using adoptive cell therapy |
| CN118652336A (zh) * | 2016-06-08 | 2024-09-17 | 普瑞赛格恩公司 | Cd33特异性嵌合抗原受体 |
| CA3049652A1 (en) * | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| EP3635132A4 (en) * | 2017-06-07 | 2021-05-26 | Intrexon Corporation | EXPRESSION OF NOVEL CELL MARKERS |
| KR102742741B1 (ko) * | 2017-10-18 | 2024-12-16 | 프레시전 인코포레이티드 | 스페이서를 포함하는 폴리펩타이드 조성물 |
| CN112533957B (zh) * | 2018-06-04 | 2026-01-16 | 普瑞赛格恩公司 | Muc16特异性嵌合抗原受体及其用途 |
| CN112672753B (zh) * | 2018-07-09 | 2025-07-08 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| CA3105816A1 (en) * | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
| US12194094B2 (en) * | 2020-07-10 | 2025-01-14 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| AU2022205683A1 (en) * | 2021-01-11 | 2023-07-06 | Precigen, Inc. | Chimeric receptor therapy |
-
2018
- 2018-10-17 KR KR1020207013590A patent/KR102742741B1/ko active Active
- 2018-10-17 SG SG11202003543WA patent/SG11202003543WA/en unknown
- 2018-10-17 EP EP18869303.0A patent/EP3697438A4/en active Pending
- 2018-10-17 US US16/163,233 patent/US11771718B2/en active Active
- 2018-10-17 JP JP2020521861A patent/JP2021500882A/ja active Pending
- 2018-10-17 IL IL273961A patent/IL273961B2/en unknown
- 2018-10-17 IL IL316522A patent/IL316522A/en unknown
- 2018-10-17 AU AU2018352984A patent/AU2018352984B2/en active Active
- 2018-10-17 CA CA3079264A patent/CA3079264A1/en active Pending
- 2018-10-17 KR KR1020247040963A patent/KR20250010043A/ko active Pending
- 2018-10-17 WO PCT/US2018/056334 patent/WO2019079486A1/en not_active Ceased
- 2018-10-17 CN CN201880082078.9A patent/CN111511391B/zh active Active
-
2023
- 2023-06-29 US US18/344,421 patent/US20230414661A1/en active Pending
- 2023-07-21 JP JP2023118889A patent/JP2023153866A/ja active Pending
- 2023-12-13 AU AU2023282226A patent/AU2023282226B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020114264A5 (enExample) | ||
| EP3472205B1 (en) | Chimeric antigen receptor | |
| JP2023091037A (ja) | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 | |
| JP7382829B2 (ja) | キメラ抗原受容体を発現するｔ細胞 | |
| JP2022109953A5 (enExample) | ||
| JP2022113880A5 (enExample) | ||
| JP2023085527A5 (enExample) | ||
| RU2019133199A (ru) | Улучшенные форматы антигенсвязывающего рецептора | |
| JP7566628B2 (ja) | キメラ抗原受容体を発現する免疫細胞 | |
| JP2022523961A5 (enExample) | ||
| JP2019150066A5 (enExample) | ||
| JP2017507917A5 (enExample) | ||
| JP2017527310A5 (enExample) | ||
| JP2020511949A5 (enExample) | ||
| RU2017133637A (ru) | Иммуномодулирующие слитые белки и пути их применения | |
| JP2020513754A5 (enExample) | ||
| RU2018118652A (ru) | Химерные конструкции антитело/т-клеточный рецептор и их применения | |
| JP2020530989A5 (enExample) | ||
| JP2020514375A5 (enExample) | ||
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| JP2018516092A5 (enExample) | ||
| JP2021514631A5 (enExample) | ||
| RU2017130985A (ru) | Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека | |
| RU2017102769A (ru) | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| JP2018525006A5 (enExample) |